Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...

Full description

Bibliographic Details
Main Authors: Satoshi Inoue, Rameshwar Patil, Jose Portilla-Arias, Hui Ding, Bindu Konda, Andres Espinoza, Dmitriy Mongayt, Janet L Markman, Adam Elramsisy, H Westley Phillips, Keith L Black, Eggehard Holler, Julia Y Ljubimova
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3280290?pdf=render

Internet

http://europepmc.org/articles/PMC3280290?pdf=render

Similar Items